Trichlorfon (Metrifonate)

Subscribe to Selected New Research on Trichlorfon

366 relevant articles (36 outcomes, 54 trials/studies) found for this Bio-Agent

Description: A organochlorophosphate cholinesterase inhibitor that is used as an insecticide for the control of flies and roaches. It is also used in anthelmintic compositions for animals. (From Merck, 11th ed)

Also Known As:

Metrifonate; Bilarcil; Chlorofos; Dipterex; Dylox; Foschlor; Metriphonate; Neguvon; Ricifon; Trichlorphon; Chlorophos; Phosphonic acid, (2,2,2-trichloro-1-hydroxyethyl)-, dimethyl ester

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 42

Organophosphorus Compounds: 131

2,2,2-trichloro-1-(2,2,2-trichloro-1-hydroxyethoxy)ethyl phosphonate

2,2-dichloro-1,1-dihydroxyethanephosphonic acid methyl ester

desmethyl-trichlorfon

Experts

1.	Cyrus, P A: 4 articles (01/2001 - 01/2000)
2.	Cummings, J L: 2 articles (01/2001 - 01/2001)
3.	Sun, Hong: 1 article (05/2007)
4.	Wang, Shoulin: 1 article (05/2007)
5.	Wang, Xinru: 1 article (05/2007)
6.	Qu, Jianhua: 1 article (05/2007)
7.	Hong, Xia: 1 article (05/2007)
8.	Wang, Yubang: 1 article (05/2007)
9.	Song, Lin: 1 article (05/2007)
10.	Schneider, L: 1 article (01/2006)

Related Diseases

1.	Alzheimer Disease (Alzheimer's Disease) 01/01/1998 - "A pilot study, and Phase I and Phase II studies of metrifonate in Alzheimer's disease (AD) patients conducted prior to the current study showed benign, dose-dependent adverse event profiles consisting primarily of gastrointestinal events, optimal daily dosing with a loading phase (in the absence of a loading dose phase, 6-8 weeks were required to attain steady-state AChE inhibition levels), and an improvement in Alzheimer's Disease Assessment Scale (ADAS) scores. " 05/01/1998 - "Metrifonate significantly improved cognitive ability, as assessed by the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), and enhanced global function, as assessed the Clinicians's Interview-Based Impression of Change with Caregiver Input (CIBIC-Plus). " 01/01/1998 - "Therefore, metrifonate is a useful treatment for the symptoms of Alzheimer's disease." 01/01/1999 - "This prospective, randomized, double-masked, placebo-controlled, parallel-group study assessed the safety and efficacy of 2 dosage regimens of once-daily metrifonate in patients with probable Alzheimer's disease (AD) of mild-to-moderate severity. " 01/01/2001 - "Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer's disease." Order ALL the reference details at left...
2.	Infection 09/01/1991 - "haematobium infections compared with metrifonate and more effective in treating S. " 07/01/1985 - "During the study period 25% of children with no evidence of infection at the start of the trial had become infected, while 45.5% of children apparently cured by the metrifonate treatment had recommenced egg excretion. " 01/01/1987 - "We have carried out an open clinical study in Somalia to evaluate the efficacy and safety of a simplified dosage schedule of metrifonate in the treatment of Schistosoma haematobium infection. " 05/01/1998 - "Medications, which can be used to prevent the infection or kill the parasite include praziquante and metrifonate." 01/01/1989 - "The degree of compliance during metrifonate therapy of Schistosoma haematobium infection has been evaluated together with its impact on drug efficacy in two rural villages in Somalia. " Order ALL the reference details at left...
3.	Schistosomiasis haematobia (Schistosomiasis haematobium) 01/01/1988 - "Efficacy of metrifonate in a highly endemic area of urinary schistosomiasis in Kenya." 11/01/1982 - "Efficacy of metrifonate in urinary schistosomiasis: comparison of reduction of Schistosoma haematobium and S. " 11/01/2009 - "The review confirmed that both the standard recommended doses of PZQ (single 40 mg/kg oral dose) and metrifonate (3x7.5-10 mg/kg oral doses administered fortnightly) are efficacious and safe in treating urinary schistosomiasis, but there is no study comparing these two regimens head-to-head. " 06/01/1991 - "During 1989 a survey for urinary schistosomiasis was carried out in children attending Kanhukamwe primary school where, 5 years previously, infected children had been treated with a single dose of metrifonate. " 06/01/1991 - "Long-term effects of single-dose metrifonate on the control of urinary schistosomiasis in an endemic area." Order ALL the reference details at left...
4.	Body Weight (Weight, Body) 01/01/2006 - "Metrifonate at various doses, fixed and loading doses, was associated with significant cognitive improvement compared to placebo, except for weekly doses where there was no difference from placebo: MMSE (metrifonate 60-80 mg/day with initial loading at 26 weeks; metrifonate 50 mg/day fixed dose with no initial loading at 26 weeks MD 1.85, 95% CI 1.06 to 2.64, p<0.00001); ADAS-Cog (metrifonate 60-80 mg/day with initial loading at 26 weeks MD -3.24, 95% CI -4.40 to -2.08, p<0.00001)In most trials, there was improvement in clinical global impression: CIBIC-Plus (metrifonate 30-55 mg/day, approximately 0.65 mg/kg body weight, with initial loading at 26 weeks MD -0.25, 95% CI -0.41 to -0.09 p=0.002; metrifonate 50 mg/day fixed dose with no initial loading at 26 weeks MD -0.20, 95% CI -0.39 to -0.01, p=0.04). " 04/01/1984 - "Thus, trichlorfon given three or four times in a dose of 10 mg/kg of body weight spaced over a period of two years was highly effective in reducing parasite load and disease in children living under hyperendemic conditions." 03/01/2007 - "The pesticide trichlorfon (125 mg/kg on days 42-44 in gestation) gives hypoplasia of the brain of the offspring without any significant reduction in their body weights. " 07/01/2009 - "The lack of effects of trichlorfon on any in vivo reproductive and fetuses endpoints above suggested that for trichlorfon, a hazard of reproductive toxicity below 50 mg/kg body weight/d maybe not expected. " 01/01/1998 - "A total of 605 patients were randomized to receive either a daily dose of oral metrifonate 40/50 mg (n = 200, by body weight <65 kg/> or =65 kg) or metrifonate 60/80 mg (n = 197, by body weight <65 kg/> or = 65 kg). " Order ALL the reference details at left...
5.	Neurobehavioral Manifestations 03/01/1998 - "These findings extend our previous report of a favorable effect of metrifonate on cognitive symptoms in AD by showing clinical, not only statistical, significance." 01/01/2006 - "OBJECTIVES: 1) To establish the efficacy of metrifonate for patients with Alzheimer's disease, in terms of cognition, global impression, functional activity, non cognitive symptoms, rate of institutionalization and mortality.2) Assess the safety and tolerability of metrifonate. " 11/01/1999 - "STUDY FINDINGS: Metrifonate is an organophosphate cholinesterase inhibitor effective in the treatment of the cognitive symptoms of Alzheimer's disease and currently under review by the U.S. " 04/01/1999 - "CONCLUSIONS: Different studies carried out with the acetylcholinesterase inhibitors donepezil, rivastigmine and metriphonate have been effective in the control of the cognitive symptoms of Alzheimer disease in the initial or moderate phases of the disease." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Praziquantel (Biltricide)
2.	Cholinesterases (Cholinesterase)
3.	Acetylcholinesterase
4.	donepezil (Aricept)
5.	rivastigmine (Exelon)
6.	Cholinesterase Inhibitors (Anticholinesterases)
7.	Tacrine (Cognex)
8.	Dichlorvos
9.	Thiabendazole (Mintezol)
10.	Physostigmine

Related Therapies and Procedures

1.	Activities of Daily Living (ADL)
2.	Drug Therapy (Chemotherapy)
3.	Institutionalization (Institutionalized Persons)
4.	Transplants (Transplant)
5.	Oral Administration

Best Treatments:
Research Summary Report
on Alzheimer Disease

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 1032 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>